{{Rsnum
|rsid=45460698
|geno1=(-;-)
|geno2=(-;AAG)
|geno3=(AAG;AAG)
|Orientation=plus
|Orientation=plus
|Chromosome=11
|position=113904832
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|Gene=HTR3B
|Gene_s=HTR3B
}}{{PharmGKB
|RSID=rs45460698
|Name_s=
|Gene_s=HTR3B
|Feature=
|Evidence=PubMed ID:12775740
|Annotation=A study in 242 cancer patients found that patients homozygous for the -100_-102delAAG deletion variant of the HTR3B promotor region experienced vomiting more frequently than all the other patients.
|Drugs=
|Drug Classes=
|Diseases=Nausea; Vomiting
|Curation Level=Curated
|PharmGKB Accession ID=PA164920380
}}

{{PharmGKB
|RSID=rs45460698
|Name_s=
|Gene_s=HTR3B
|Feature=
|Evidence=PubMed ID:15389765
|Annotation=This study observed a significant underrepresentation of the 3 bp deletion -100_-102delAAG of the HTR3B gene promoter region in an extended sample of 162 bipolar affected patients compared to controls.
|Drugs=
|Drug Classes=
|Diseases=Psychophysiologic Disorders
|Curation Level=Curated
|PharmGKB Accession ID=PA164920379
}}

{{PMID Auto
|PMID=21840870
|Title=Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs45460698
|n_genomes=4
|n_genomes_annotated=0
|n_haplomes=4
|n_articles=2
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}
{{on chip | 23andMe v3}}